戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gylated IFN-alpha, ribavirin, and telaprevir/boceprevir.
2 could affect binding of telaprevir more than boceprevir.
3 s were similar with 24 weeks and 44 weeks of boceprevir.
4 ginterferon and ribavirin with telaprevir or boceprevir.
5 ts of the phase III trials for telaprevir or boceprevir.
6 response to prior therapy with telaprevir or boceprevir.
7 ketoamide fragment of the protease inhibitor boceprevir.
8 kin rash and anal discomfort by switching to boceprevir.
9 PI/r resulted in reduced exposures of PI and boceprevir.
10 ded for combined HIV/HCV treatment including boceprevir.
11 ho failed earlier therapy with telaprevir or boceprevir.
12               The HCV NS3 protease inhibitor Boceprevir (1) was reported by our research group and ef
13 han the first generation clinical candidate, boceprevir (1, Sch 503034), is discussed.
14 ibavirin without (46%) or with telaprevir or boceprevir (12%).
15  pegylated interferon, ribavirin, and either boceprevir (2 trials) or telaprevir (4 trials) was assoc
16                            Among those given boceprevir, 53.9% of relapsers, 38.3% of partial respond
17 l subjects were randomly assigned to receive boceprevir 800 mg every 8 hours for 9 days plus a single
18 wed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a day for 24 weeks (PR4/PR
19                 After washout, they received boceprevir (800 mg three times a day) for 11 days plus s
20             After washout, subjects received boceprevir (800 mg three times a day) for 7 days plus si
21 In part 2B, 10 subjects received single-dose boceprevir (800 mg) and 24 hours later received boceprev
22  cyclosporine (100 mg) on day 1, single-dose boceprevir (800 mg) on day 3, and concomitant cyclospori
23 eprevir (800 mg) and 24 hours later received boceprevir (800 mg) plus tacrolimus (0.5 mg).
24                            Subjects received boceprevir (800 mg, 3 times daily) for 6 days and then r
25  and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon
26                                              Boceprevir, a potent oral HCV-protease inhibitor, has be
27                                              Boceprevir, a protease inhibitor that binds to the HCV n
28 istinct from the FDA-approved telaprevir and boceprevir alpha-ketoamide inhibitors, are required.
29  interactions have been demonstrated between boceprevir, an HCV protease inhibitor, and frequently pr
30                    We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhib
31 n about pharmacokinetic interactions between boceprevir and antiretroviral drugs.
32 low-level resistance to telaprevir (TVR) and boceprevir and confers high-level resistance (>70-fold)
33 omponents of hepatitis C protease inhibitors boceprevir and narlaprevir, and known SARS-CoV-1 proteas
34   To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment o
35 treatment With HCV Serine Protease Inhibitor Boceprevir and Pegintron/Rebetol 2 (RESPOND-2) study (tr
36 treatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) re
37 rol group (n = 66) received a combination of boceprevir and PR, dosed in accordance with boceprevir's
38 e absence of a drug-drug interaction between boceprevir and raltegravir, an HIV integrase inhibitor.
39 ess the pharmacokinetic interactions between boceprevir and ritonavir-boosted protease inhibitors (PI
40                                              Boceprevir and telaprevir are inhibitors and substrates
41                        We analyzed data from boceprevir and telaprevir clinical trials to obtain a co
42                Retrospective analyses of the boceprevir and telaprevir phase 3 trial data demonstrate
43 dition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (pegin
44                          Analyses of Phase 2 boceprevir and telaprevir trials indicated subjects with
45 nt emergence of two new protease inhibitors, boceprevir and telaprevir, to enhance the modern treatme
46                                  These DAAs, boceprevir and telaprevir, when given with pegylated int
47  US Food and Drug Administration approval of boceprevir and telaprevir--two protease inhibitors--the
48 t promising protease inhibitors, telaprevir, boceprevir, and ITMN-191, has emerged in clinical trials
49                                       During boceprevir- and telaprevir-based treatment, subjects wit
50                                              Boceprevir- and telaprevir-based treatments for chronic
51                               Telaprevir and boceprevir are structurally similar, and share cross-res
52 followed by guideline-based treatment (using boceprevir as the direct-acting antiviral agent) of thos
53 r by the NS3 protease inhibitors telaprevir, boceprevir, asunaprevir, simeprevir, vaniprevir, faldapr
54                                    The GM of boceprevir AUC(0-8h), C(max), and C(8h) were 5.45 (95% C
55 ignificantly affect boceprevir exposure, but boceprevir AUC(tau) was reduced by 45% and 32% when coad
56                                              Boceprevir-based and telaprevir-based triple therapy wit
57 stopping rules for patients destined to fail boceprevir-based combination therapy in order to minimiz
58                                              Boceprevir-based groups had higher rates of anaemia (227
59 static hepatitis treated with telaprevir- or boceprevir-based triple therapy at 6 centers (CRUSH-C co
60 hibitors VX-950 (telaprevir) and SCH 503034 (boceprevir) benefited from covalent adduct formation.
61                                              Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN)
62                                              Boceprevir (BOC) and telaprevir (TPV), when added to peg
63 bavirin (RBV) for 48 weeks, PEG-IFN/RBV plus boceprevir (BOC) or telaprevir (TEL) for 48 weeks, and s
64 TT) with peginterferon alpha, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective t
65 In clinical trials with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a
66 SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untre
67 esponse-guided shortening of the duration of boceprevir (BOC)-based triple therapy in human immunodef
68 esponse-guided shortening of the duration of boceprevir (BOC)-based triple therapy in human immunodef
69 ovalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bio
70 inant was highly resistant to telaprevir and boceprevir, but most sensitive to other protease inhibit
71                    In Phase 3 trials P05216 (boceprevir), C216 (telaprevir), and 108 (telaprevir), de
72 ellular antiviral activity, including GC376, boceprevir, calpain inhibitors II, and XII, with each co
73                        Coadministration with boceprevir decreased RTV AUC during a dosing interval ta
74                                              Boceprevir decreased the exposure of all PI/r, with area
75           ATV/r did not significantly affect boceprevir exposure, but boceprevir AUC(tau) was reduced
76 ents receiving peginterferon, ribavirin, and boceprevir for HCV infection.
77      Study arms that evaluated telaprevir or boceprevir for unlicensed durations or without both pegy
78 pproval of two new DAA drugs--telaprevir and boceprevir--for use in pegylated interferon-based and ri
79 V protease inhibitors such as telaprevir and boceprevir, given in combination with pegylated IFN and
80               40 (63%) of 64 patients in the boceprevir group had an SVR at follow-up week 24, compar
81 p) or 800 mg boceprevir three times per day (boceprevir group) for 44 weeks.
82 response was significantly higher in the two boceprevir groups (group 2, 59%; group 3, 66%) than in t
83                         Patients in all four boceprevir groups had higher rates of SVR than did the c
84  Anemia was significantly more common in the boceprevir groups than in the control group, and erythro
85 should be anticipated when administered with boceprevir, guided by close monitoring of cyclosporine b
86 al for drug interactions with telaprevir and boceprevir had not been answered.
87 previr response-guided therapy (BOC-RGT); 2) boceprevir IL28B genotype-guided strategy (BOC-IL28B); 3
88                                              Boceprevir in combination with peginterferon-ribavirin c
89 elaprevir had greater relative efficacy than boceprevir in patients who had previously relapsed.
90 , and we further confirmed its resistance to boceprevir in protease enzyme and replicon assay.
91                                  Concomitant boceprevir increased the area under the concentration-ti
92                                  Concomitant boceprevir increased the AUC(inf) and C(max) of tacrolim
93     The hepatitis C virus protease inhibitor boceprevir is a strong inhibitor of cytochrome P450 3A4
94 ginterferon and ribavirin with telaprevir or boceprevir is the standard treatment of hepatitis C viru
95 suspected cause whereby CYP3A4 inhibition by boceprevir led to increased exposures of doxazosin, tams
96                The key structural feature in Boceprevir, Merck's new drug treatment for hepatitis C,
97 s) were given either telaprevir (n = 299) or boceprevir (n = 212) for 48 weeks.
98 elaprevir had greater relative efficacy than boceprevir (odds ratio [OR], 2.61 [95% confidence interv
99 0 mg) on day 3, and concomitant cyclosporine/boceprevir on day 4.
100 (RTV) 100 mg on days 10-31, plus concomitant boceprevir on days 25-31.
101 e genotype 1a protease, co-crystallized with boceprevir or a telaprevir-like ligand, and then identif
102 nd ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir.
103                           The combination of boceprevir or telaprevir with peginterferon-alfa and rib
104 ectiveness using current triple therapy with boceprevir or telaprevir, but also modeled new, more-pot
105 nfected patients who are currently receiving boceprevir or telaprevir-based therapy against HCV show
106 OR, 3.24 [95% CI, 2.56-4.10]); telaprevir vs boceprevir (OR, 1.06 [95% CI, 0.75-1.47]).
107  891) (OR, 8.32 [5.69-12.36]); telaprevir vs boceprevir (OR, 1.27 [95% CI, .71-2.30]).
108  peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy
109 nt of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to ane
110  coadministration had a meaningful effect on boceprevir pharmacokinetics.
111 revious virologic failure with telaprevir or boceprevir plus peginterferon alfa-ribavirin).
112                  Three patients who received boceprevir plus peginterferon-ribavirin and four control
113 ron-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, an
114 ron-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 32 weeks, an
115 an additional 20 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks.
116 an additional 12 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks.
117 s efficacy and safety of triple therapy with boceprevir plus pegylated interferon alfa-2b (peginterfe
118                            Administration of boceprevir plus tacrolimus requires significant dose red
119 28B genotype-guided strategy (BOC-IL28B); 3) boceprevir rapid virologic response (RVR)-guided strateg
120                                           In boceprevir recipients, the combination of 2 stopping rul
121 ose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2
122                                              Boceprevir represents a new treatment option for hepatit
123  the following five competing strategies: 1) boceprevir response-guided therapy (BOC-RGT); 2) bocepre
124                                  Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was com
125  boceprevir and PR, dosed in accordance with boceprevir's US product circular.
126 improve upon our current clinical candidate, Boceprevir (SCH 503034), extensive SAR studies were perf
127      Recently, we disclosed the discovery of Boceprevir, SCH 503034 (1), a novel, potent, selective,
128 dies with our first generation HCV inhibitor Boceprevir, SCH 503034 (1), presented at the 56th Annual
129 gylated interferon and ribavirin plus either boceprevir, telaprevir, or simeprevir.
130 ts were more common in patients who received boceprevir than in control patients: 26 (41%) versus nin
131 ors Telaprevir, BILN2061, ITMN-191, SCH6 and Boceprevir; the NS5B polymerase inhibitor AG-021541; and
132 3); or peginterferon alfa-2b, ribavirin, and boceprevir three times a day for 28 weeks (PRB28; n=107)
133 (400-1000 mg) plus peginterferon alfa-2b and boceprevir three times a day for 48 weeks (low-dose PRB4
134 lus either placebo (control group) or 800 mg boceprevir three times per day (boceprevir group) for 44
135                              The addition of boceprevir to peginterferon-ribavirin resulted in signif
136                              The addition of boceprevir to standard therapy with peginterferon-ribavi
137 ddition of the direct-acting antiviral agent boceprevir to standard treatment with peginterferon and
138 thropoietin was administered in 41 to 46% of boceprevir-treated patients and 21% of controls.
139                  Compared with dual therapy, boceprevir triple therapy increased risk for hematologic
140 ks of peginterferon alpha-2b, ribavirin, and boceprevir (triple therapy).
141 3/4A protease, telaprevir (Incivik((R))) and boceprevir (Victrelis((R))).
142 protease inhibitors telaprevir (Incivek) and boceprevir (Victrelis) are the first direct-acting antiv
143 avir AUC(0-12h) and C(max) for raltegravir + boceprevir vs raltegravir alone were 1.04 (90% CI, .88-1
144 sma concentration (C(max)) for raltegravir + boceprevir vs raltegravir alone were 4.27 (95% confidenc
145                    Treatment-naive patients: boceprevir vs standard of care (n = 1417) (OR, 3.06 [95%
146      Total treatment-experienced population: boceprevir vs standard of care (n = 604) (OR, 6.53 [95%
147 hase II clinical study of protease inhibitor boceprevir, we calculated the selection pressure for all
148            At key RGT timepoints (week 8 for boceprevir, week 4 for telaprevir), subjects with detect
149 able for an additional 8 (telaprevir) to 20 (boceprevir) weeks (extended RVR).
150                               Telaprevir and boceprevir were approved in 2011 for use against genotyp
151 , novel HCV NS3/4A PIs (PIs), telaprevir and boceprevir, were approved for use in combination with Pe
152 atitis C protease inhibitors, telaprevir and boceprevir, were shown to have antiviral activity in hep
153  may reduce the effectiveness of PI/r and/or boceprevir when coadministered.
154                 These agents, telaprevir and boceprevir, when used in combination with pegylated inte
155  pharmacokinetic interaction study evaluated boceprevir with cyclosporine (part 1) and tacrolimus (pa
156                          Coadministration of boceprevir with cyclosporine/tacrolimus was well tolerat
157 mparison with peginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly im
158                Concomitant administration of boceprevir with PI/r resulted in reduced exposures of PI
159                Concomitant administration of boceprevir with these drugs should be avoided.

 
Page Top